enzastaurin has been researched along with thalidomide in 6 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 9,789 | 1,385 | 4,342 |
| Protein | Taxonomy | enzastaurin (IC50) | thalidomide (IC50) |
|---|---|---|---|
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
| Protein cereblon | Homo sapiens (human) | 1.38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hagemeister, FB | 1 |
| Bari, A; Civallero, M; Cosenza, M; Sacchi, S | 1 |
| Anderson, KC; Podar, K | 1 |
| Bari, A; Civallero, M; Cosenza, M; Grisendi, G; Marcheselli, L; Roat, E; Sacchi, S | 1 |
| Ogura, M | 1 |
| Bari, A; Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
2 review(s) available for enzastaurin and thalidomide
| Article | Year |
|---|---|
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
1 trial(s) available for enzastaurin and thalidomide
| Article | Year |
|---|---|
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
3 other study(ies) available for enzastaurin and thalidomide
| Article | Year |
|---|---|
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Indoles; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Rituximab; Thalidomide | 2011 |
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Humans; Indoles; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2012 |
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Indoles; Lenalidomide; Lymphoma, Mantle-Cell; Male; Signal Transduction; Thalidomide | 2015 |